scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
Journal ArticleDOI

A brief overview of various vaccines against nCOVID19, including safety, efficacy, reported cases, clinical trials, and progress

TL;DR: In this article , the first half of 2021 has seen the introduction of SARS-CoV-2 vaccinations in several countries, after the exceptional speed of vaccine development and testing in 2020.
Journal ArticleDOI

Correction to: The attitude of fully vaccinated individuals towards COVID-19 vaccine booster dose: a transverse study from Jordan

TL;DR: In this paper , the authors assess individuals' attitudes towards COVID-19 booster vaccination dose and determine predictors of this attitude using a cross-sectional descriptive design, and find that participants had mixed attitudes towards the booster dose with about half of the participants willing to take the booster.
Journal ArticleDOI

Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy

TL;DR: In this article , the differences in the clinical characteristics and severity of lung impairment, assessed by quantitative lung CT scan, between vaccinated and non-vaccinated hospitalized patients with COVID-19; and to identify the variables with best prognostic prediction according to SARS-CoV-2 vaccination status.
Journal ArticleDOI

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands

TL;DR: In this article , the authors describe the profile of spontaneously reported adverse events following COVID-19 vaccination in the Netherlands, including the primary and booster series, and observe a high degree of similarity in local and systemic adverse events per vaccination moment.
References
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

TL;DR: The specific objectives of this report were to assess the safety and humoral and cellular immunogenicity of a single-dose and two-dose schedule in adults older than 55 years, and safety, as measured by the occurrence of serious adverse events.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -